Patents by Inventor James R. Tata

James R. Tata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8637555
    Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: January 28, 2014
    Assignees: Arena Pharmaceuticals, Inc., Merck & Co., Inc.
    Inventors: Graeme Semple, Thomas Schrader, Philip J. Skinner, Steven L. Colletti, Tawfik Gharbaoui, Jason E. Imbriglio, Jae-Kyu Jung, Rui Liang, Subharekha Raghavan, Darby Schmidt, James R. Tata
  • Patent number: 8318760
    Abstract: Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: November 27, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. Stelmach, Keith G. Rosauer, Emma R. Parmee, James R. Tata
  • Publication number: 20120178750
    Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: March 19, 2012
    Publication date: July 12, 2012
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Subharekha Raghavan, Steven L. Colletti, Fa-Xiang Ding, Hong Shen, James R. Tata, Ashley Rouse Lins, Abigail Lee Smenton, Weichun Chen, Darby Rye Schmidt, George Scott Tria
  • Patent number: 8168649
    Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: May 1, 2012
    Assignee: Merk Sharp & Dohme Corp.
    Inventors: Subharekha Raghavan, Steven L. Colletti, Fa-Xiang Ding, Hong Shen, James R. Tata, Ashley Rouse Lins, Abigail Lee Smenton, Weichun Chen, Darby Rye Schmidt, George Scott Tria
  • Patent number: 7968589
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: June 28, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. Stelmach, Emma R. Parmee, James R. Tata, Keith G. Rosauer, Ronald M. Kim, Amy R. Bittner, Jiang Chang, Christopher Joseph Sinz
  • Publication number: 20100144778
    Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: June 26, 2006
    Publication date: June 10, 2010
    Inventors: Subharekha Raghavan, Steven L. Colletti, Fa-Xiang Ding, Hong Shen, James R. Tata, Ashley Rouse Lins, Abigail Lee Smenton, Weichun Chen, Darby Rye Schmidt, George Scott Tria
  • Publication number: 20100144824
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: February 9, 2010
    Publication date: June 10, 2010
    Inventors: JOHN E. STELMACH, EMMA R. PARMEE, JAMES R. TATA, KEITH G. ROSAUER, RONALD M. KIM, AMY R. BITTNER, JIANG CHANG, CHRISTOPHER JOSEPH SINZ
  • Patent number: 7687534
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: March 30, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. Stelmach, Emma R. Parmee, James R. Tata, Keith G. Rosauer, Ronald M. Kim, Amy R. Bittner, Jiang Chang, Christopher Joseph Sinz
  • Publication number: 20100004158
    Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: September 27, 2007
    Publication date: January 7, 2010
    Inventors: John E. Stelmach, Emma R. Parmee, James R. Tata, Keith G. Rosauer, Ronald M. Kim, Amy R. Bittner, Jiang Chang, Christopher Joseph Sinz
  • Publication number: 20090258862
    Abstract: Compounds of the formula (I): as well as pharmaceutically acceptable salts and solvates are disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: August 25, 2006
    Publication date: October 15, 2009
    Inventors: Steven L. Colletti, Hong Shen, James R. Tata, Michael J. Szymonifka
  • Publication number: 20090170891
    Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: April 6, 2007
    Publication date: July 2, 2009
    Inventors: Steven L. Colletti, James R. Tata, Weichun Chen, Richard T. Beresis, Fa-Xiang Ding, Darby Rye Schmidt, Hong Shen, Subharekha Raghavan
  • Publication number: 20090054423
    Abstract: The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: April 7, 2006
    Publication date: February 26, 2009
    Inventors: Jason E. Imbriglio, Steven L. Colletti, James R. Tata, Rui Liang, Subharekha Raghavan, Darby R. Schmidt, Abigail L. Smenton, Sook Yee Chan
  • Publication number: 20090042926
    Abstract: The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: December 20, 2006
    Publication date: February 12, 2009
    Inventors: Jason Imbriglio, Steven L. Colletti, James R. Tata, Richard T. Beresis, Daria Marley, Subharekha Raghavan, Darby Rye Schmidt, Ashley Rouse Lins, Abigail L. Smenton, Weichun Chen, Hong Shen, Fa-Xiang Ding, Rena Bodner
  • Patent number: 7411073
    Abstract: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity and/or metabolism. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Amjad Ali, Richard Beresis, Steven L. Colletti, Donald W. Graham, James R. Tata, Christopher F. Thompson
  • Publication number: 20080161347
    Abstract: Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: March 17, 2006
    Publication date: July 3, 2008
    Applicant: MERCK & CO., INC.
    Inventors: John E. Stelmach, Keith G. Rosauer, Emma R. Parmee, James R. Tata
  • Patent number: 7196106
    Abstract: The present invention addresses substituted cyanothiophene derivatives of the formula I: as well as compositions containing such compounds and methods of treatment. The compounds in the present invention are glucagon antagonists. The compounds block the action of glucagon at its receptor and thereby decrease the levels of plasma glucose providing a treatment of diabetes.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: March 27, 2007
    Assignee: Merck & Co., Inc
    Inventors: Joseph L. Duffy, Elizabeth Louise Campbell, Brian A. Kirk, Rui Liang, James R. Tata, Kevin T. Chapman, Zenon Konteatis
  • Publication number: 20040097552
    Abstract: The present invention addresses substituted cyanothiophene derivatives of the formula I: 1
    Type: Application
    Filed: November 4, 2003
    Publication date: May 20, 2004
    Inventors: Joseph L. Duffy, Elizabeth Louise Campbell, Brian A. Kirk, Rui Liang, James R. Tata, Kevin T. Chapman, Zenon Konteatis
  • Publication number: 20040097557
    Abstract: The present invention addresses substituted cyanothiophene derivatives of the formula I: 1
    Type: Application
    Filed: November 12, 2003
    Publication date: May 20, 2004
    Inventors: Joseph L. Duffy, Rui Liang, Elizabeth Louise Campbell, Sajjad A. Qureshi, Bei B. Zhang, James R. Tata, Brian A. Kirk, Kevin T. Chapman, Zenon Konteatis
  • Patent number: 6642237
    Abstract: &ggr;-Hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamide compounds are inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.
    Type: Grant
    Filed: November 21, 2000
    Date of Patent: November 4, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James R. Tata, Kevin T. Chapman, Joseph Leslie Duffy, Nancy J. Kevin, Yuan Cheng, Thomas A. Rano, Fengqi Zhang, Tracy Huening, Brian Anthony Kirk, Zhijian Lu, Subharekha Raghavan, Fred J. Fleitz, Daniel E. Petrillo, Joseph D. Armstrong, III, Richard J. Varsolona, David Askin, R. Scott Hoerrner, Robert Purick
  • Patent number: 6589962
    Abstract: Certain &agr;-hydroxy-&ggr;-[[(carbocyclic- or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives are described as inhibitors of HIV protease and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. These compounds are effective against HIV viral mutants which are resistant to HIV protease inhibitors currently used for treating AIDS and HIV infection.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: July 8, 2003
    Assignee: Merck & Co., Inc.
    Inventors: James R Tata, Zhijian Lu, Subharekha Raghavan, Tracy T. Huening, Thomas A. Rano, Mark G. Charest